{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:20:26Z","timestamp":1782534026041,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AN received lecturing honoraria and research support from Sanofi Genzyme, Takeda, and Amicus."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>During the coronavirus disease-19 (COVID-19) pandemic, vulnerable populations must be identified to prevent increased mortality. Fabry disease (FD) is a rare X-linked lysosomal storage disorder leading to chronic kidney disease (CKD), cardiomyopathy, pneumonopathy and premature strokes. Little is known whether SARS-CoV-2 infection bears a particular risk for FD patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>During pandemic (02.2020\u201303.2021) we have regularly followed 104 unvaccinated FD patients. In 61\/104, titre of serum antibodies against SARS-CoV-2 were measured and SARS-CoV-2 PCR test was performed in symptomatic patients or in case of positivity of other family members. The symptoms and duration of COVID-19 were reported by the patients or the treating physician.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>No deaths or intensive care unit hospitalizations occurred. 13\/104 (12.5%) were diagnosed with SARS-CoV-2 infection (16.7% (4\/24) men 12.2% (6\/49) women of classic phenotype, 25% (3\/12) of the men and 0% (0\/8) of the women of later- onset phenotype). Of those, 2\/13 (15.4%) patients\u2014both kidney transplant recipients\u2014developed severe COVID-19, were hospitalized, and required a high-flow oxygen mask. The rest either developed mild COVID-19 manifestations (8\/13, 61.5%) or were asymptomatic (3\/13, 23.1%). 2\/13 (15.4%) of the patients experienced Fabry pain crisis and 3\/13 (23.1%) long COVID-19 like symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Similar to the general population, in FD patients the risk for severe COVID-19 seems to be driven by the immune system rather than by FD itself. Immunosuppression in kidney transplant recipients represented the highest risk in this population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02386-7","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T08:02:54Z","timestamp":1656403374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["COVID-19 in Fabry disease: a reference center prospective study"],"prefix":"10.1186","volume":"17","author":[{"given":"Christina","family":"Bothou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanja","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"von Eckardstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Beuschlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4119-5516","authenticated-orcid":false,"given":"Albina","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"issue":"1","key":"2386_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41581-020-00357-4","volume":"17","author":"L Perico","year":"2021","unstructured":"Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol. 2021;17(1):46\u201364.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"2386_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","volume":"123","author":"A Nowak","year":"2018","unstructured":"Nowak A, Mechtler TP, Hornemann T, Gawinecka J, Theswet E, Hilz MJ, et al. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease. Mol Genet Metab. 2018;123(2):148\u201353.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2386_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"A Mehta","year":"2004","unstructured":"Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34(3):236\u201342.","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"2386_CR4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/jimd.12167","volume":"43","author":"A Nowak","year":"2020","unstructured":"Nowak A, Huynh-Do U, Krayenbuehl PA, Beuschlein F, Schiffmann R, Barbey F. Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort. J Inherit Metab Dis. 2020;43(2):326\u201333.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"2386_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ymgme.2021.02.001","volume":"132","author":"D Moreno-Martinez","year":"2021","unstructured":"Moreno-Martinez D, Aguiar P, Auray-Blais C, Beck M, Bichet DG, Burlina A, et al. Standardising clinical outcomes measures for adult clinical trials in Fabry disease: a global Delphi consensus. Mol Genet Metab. 2021;132(4):234\u201343.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"2386_CR6","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT, et al. Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study. J Am Soc Nephrol. 2017;28(5):1631\u201341.","journal-title":"J Am Soc Nephrol"},{"key":"2386_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/TACG.S146022","volume":"12","author":"JP Oliveira","year":"2019","unstructured":"Oliveira JP, Ferreira S. Multiple phenotypic domains of Fabry disease and their relevance for establishing genotype-phenotype correlations. Appl Clin Genet. 2019;12:35\u201350.","journal-title":"Appl Clin Genet"},{"issue":"3","key":"2386_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124(3):189\u2013203.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2386_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/ehf2.12647","volume":"7","author":"C Wanner","year":"2020","unstructured":"Wanner C, Feldt-Rasmussen U, Jovanovic A, Linhart A, Yang M, Ponce E, et al. Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis. ESC Heart Fail. 2020;7(3):825\u201334.","journal-title":"ESC Heart Fail."},{"key":"2386_CR10","doi-asserted-by":"crossref","unstructured":"Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019;19.","DOI":"10.1016\/j.ymgmr.2019.100471"},{"issue":"6","key":"2386_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/ckj\/sfaa227","volume":"13","author":"DA Laney","year":"2020","unstructured":"Laney DA, Germain DP, Oliveira JP, Burlina AP, Cabrera GH, Hong GR, et al. Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. Clin Kidney J. 2020;13(6):913\u201325.","journal-title":"Clin Kidney J"},{"key":"2386_CR12","unstructured":"Clinical Spectrum of SARS-CoV-2 Infection [Internet]. 2020."},{"issue":"2","key":"2386_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S2213-2600(21)00031-X","volume":"9","author":"P Venkatesan","year":"2021","unstructured":"Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9(2):129.","journal-title":"Lancet Respir Med"},{"key":"2386_CR14","unstructured":"People with Certain Medical Conditions [Internet]. Available at: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-with-medical-conditions.html. 2020."},{"issue":"11","key":"2386_CR15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","volume":"11","author":"S Waldek","year":"2009","unstructured":"Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med. 2009;11(11):790\u20136.","journal-title":"Genet Med"},{"issue":"3","key":"2386_CR16","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1164\/ajrccm.155.3.9116979","volume":"155","author":"LK Brown","year":"1997","unstructured":"Brown LK, Miller A, Bhuptani A, Sloane MF, Zimmerman MI, Schilero G, et al. Pulmonary involvement in Fabry disease. Am J Respir Crit Care Med. 1997;155(3):1004\u201310.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2386_CR17","doi-asserted-by":"publisher","first-page":"e000277","DOI":"10.1136\/bmjresp-2018-000277","volume":"5","author":"D Franzen","year":"2018","unstructured":"Franzen D, Haile SR, Kasper DC, Mechtler TP, Flammer AJ, Krayenbuhl PA, et al. Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy. BMJ Open Respir Res. 2018;5(1):e000277.","journal-title":"BMJ Open Respir Res"},{"issue":"3","key":"2386_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/jobm.202000537","volume":"61","author":"SB Kadam","year":"2021","unstructured":"Kadam SB, Sukhramani GS, Bishnoi P, Pable AA, Barvkar VT. SARS-CoV-2, the pandemic coronavirus: molecular and structural insights. J Basic Microbiol. 2021;61(3):180\u2013202.","journal-title":"J Basic Microbiol"},{"issue":"3","key":"2386_CR19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ymgme.2020.04.002","volume":"130","author":"A Sechi","year":"2020","unstructured":"Sechi A, Macor D, Valent S, Da Riol RM, Zanatta M, Spinelli A, et al. Impact of COVID-19 related healthcare crisis on treatments for patients with lysosomal storage disorders, the first Italian experience. Mol Genet Metab. 2020;130(3):170\u20131.","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"2386_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ymgme.2020.07.008","volume":"131","author":"E Riccio","year":"2020","unstructured":"Riccio E, Pieroni M, Limoneglli G, Pisani A. Impact of COVID-19 pandemic on patients with Fabry disease: an Italian experience. Mol Genet Metab. 2020;131(1\u20132):124\u20135.","journal-title":"Mol Genet Metab"},{"issue":"1147","key":"2386_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/postgradmedj-2020-138577","volume":"97","author":"A Parasher","year":"2021","unstructured":"Parasher A. COVID-19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J. 2021;97(1147):312\u201320.","journal-title":"Postgrad Med J"},{"key":"2386_CR22","doi-asserted-by":"crossref","unstructured":"Gomez-Lujan M, Cruzalegui C, Aguilar C, Alvarez-Vargas M, Segura-Saldana P. When Frequent (Pandemic) Occurs in a Non-Frequent Disease: Covid-19 and Fabry Disease: Report of Two Cases. Jpn J Infect Dis. 2020.","DOI":"10.7883\/yoken.JJID.2020.729"},{"key":"2386_CR23","doi-asserted-by":"crossref","unstructured":"Ghosh S, Dellibovi-Ragheb TA, Kerviel A, Pak E, Qiu Q, Fisher M, et al. beta-Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway. Cell. 2020;183(6):1520-+.","DOI":"10.1016\/j.cell.2020.10.039"},{"key":"2386_CR24","doi-asserted-by":"crossref","unstructured":"Guo C, Tsai SJ, Ai Y, Li M, Pekosz A, Cox A, et al. The D614G Mutation Enhances the Lysosomal Trafficking of SARS-CoV-2 Spike. bioRxiv. 2020.","DOI":"10.1101\/2020.12.08.417022"},{"issue":"7","key":"2386_CR25","doi-asserted-by":"publisher","first-page":"e0180437","DOI":"10.1371\/journal.pone.0180437","volume":"12","author":"DP Franzen","year":"2017","unstructured":"Franzen DP, Nowak A, Haile SR, Mottet D, Bonani M, Dormond O, et al. Long-term follow-up of pulmonary function in Fabry disease: A bi-center observational study. PLoS ONE. 2017;12(7):e0180437.","journal-title":"PLoS ONE"},{"key":"2386_CR26","doi-asserted-by":"publisher","first-page":"110282","DOI":"10.1016\/j.mehy.2020.110282","volume":"144","author":"RC Reisin","year":"2020","unstructured":"Reisin RC, Rozenfeld P, Bonardo P. Fabry disease patients have an increased risk of stroke in the COVID-19 ERA. A hypothesis. Med Hypotheses. 2020;144:110282.","journal-title":"Med Hypotheses"},{"issue":"3","key":"2386_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.7883\/yoken.JJID.2020.729","volume":"74","author":"M Gomez-Lujan","year":"2021","unstructured":"Gomez-Lujan M, Cruzalegui C, Aguilar C, Alvarez-Vargas M, Segura-Saldana P. When Frequent (Pandemic) Occurs in a Non-Frequent Disease: COVID-19 and Fabry Disease: Report of Two Cases. Jpn J Infect Dis. 2021;74(3):228\u201332.","journal-title":"Jpn J Infect Dis"},{"key":"2386_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2021.100802","volume":"29","author":"R Mahoney","year":"2021","unstructured":"Mahoney R, Lee GK, Zepeda JP, Gabriel C, Hall K, Edwards R, et al. Severe manifestations and treatment of COVID-19 in a transplanted patient with Fabry disease. Mol Genet Metab Rep. 2021;29: 100802.","journal-title":"Mol Genet Metab Rep"},{"issue":"4","key":"2386_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41577-019-0244-2","volume":"20","author":"M Akkaya","year":"2020","unstructured":"Akkaya M, Kwak K, Pierce SK. B cell memory: building two walls of protection against pathogens. Nat Rev Immunol. 2020;20(4):229\u201338.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"2386_CR30","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1681\/ASN.2021040490","volume":"32","author":"C Danthu","year":"2021","unstructured":"Danthu C, Hantz S, Dahlem A, Duval M, Ba B, Guibbert M, et al. Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients. J Am Soc Nephrol. 2021;32(9):2153\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"2386_CR31","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1111\/ajt.16702","volume":"21","author":"M Miele","year":"2021","unstructured":"Miele M, Busa R, Russelli G, Sorrentino MC, Di Bella M, Timoneri F, et al. Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients. Am J Transplant. 2021;21(8):2919\u201321.","journal-title":"Am J Transplant"},{"issue":"13","key":"2386_CR32","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1056\/NEJMc2111462","volume":"385","author":"VG Hall","year":"2021","unstructured":"Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385(13):1244\u20136.","journal-title":"N Engl J Med"},{"issue":"10310","key":"2386_CR33","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/S0140-6736(21)02096-1","volume":"398","author":"M Prendecki","year":"2021","unstructured":"Prendecki M, Thomson T, Clarke CL, Martin P, Gleeson S, De Aguiar RC, et al. Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients. Lancet. 2021;398(10310):1482\u20134.","journal-title":"Lancet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02386-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02386-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02386-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T08:09:12Z","timestamp":1656403752000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02386-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2386"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02386-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,28]]},"assertion":[{"value":"21 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The central ethical Committee of the University of Zurich approved this study and by the Zurich Ethics Committee (KEK-ZH-Nr. 2014-0534 and 2021-01958). Written informed consent was obtained from all patients, in accordance with the Declaration of Helsinki of 1975 as revised in 2000.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"250"}}